

			Revenue estimates million DKR				
	Royalty	Peaksale	2021	2022	2023	2024	2025
Daratumumab (CD38) MM (Janssen Biotech)	17.5%	10B\$USD	6450	7450	8450	9450	10500
AL Amyloidosis (Dara)							
Non MM blod cancers : phase 2 (Dara)							
Ofatumumab (CD20) MS (Novartis Pharma)	10%	2.5B\$USD	250	500	800	1100	1500
Teprotumumab (IGF-1R) Thyroid eye disease (Horizon)	7%	3.5B\$USD	450	730	960	1190	1470
Amivantamab (Janssen)	10%	1B\$USD	75	155	250	400	600
Tisotumab Vedotin (Cervical) Seagen Inc.	50/50	500M\$USD	90	180	375	750	1500
Ovarian Cancer	50/50						
Solid tumors	50/50						
Epcoritamab - 1st sale Q4 - 2022 AbbVie	50/50	5B\$USD	0	250	5000	10000	15000
HexaBody-CD38							
DuoBody, BNT311-GEN1046 - Phase 1/2 data H2-2021 (BioNTech) - solid tumors	50/50						
Total			7315	9265	15835	22890	30570

Revision 6 - April 05-2021

USD / DKK

6.0